SCHEMBL3245222

SCHEMBL3245222

COC(=O)c1ccc(OCc2ccccc2)c(OCc2ccccc2)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMPD1 P17405 2/20 0.67
HDAC1 Q13547 1/20 0.67
HDAC8 Q9BY41 1/20 0.67
HDAC6 Q9UBN7 1/20 0.67
RAB9A P51151 3/20 0.64
HPGD P15428 2/20 0.64
SMN1; SMN2 Q16637 2/20 0.64
NPC1 O15118 2/20 0.64
LMNA P02545 2/20 0.62
MAPT P10636 3/20 0.61
CYP1A2 P05177 1/20 0.61
CYP3A4 P08684 1/20 0.61
CYP2C9 P11712 1/20 0.61
CYP2C19 P33261 1/20 0.61
KDM4E B2RXH2 1/20 0.58
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58
RXRA P19793 1/20 0.56
ATM Q13315 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bicarbonate SCHEMBL5504809 0.96 SMPD1 (0.62) SMPD1HDAC1HDAC8HDAC6RAB9A
Bicarbonate SCHEMBL5504807 0.96 SMPD1 (0.62) SMPD1HDAC1HDAC8HDAC6RAB9A
SCHEMBL18660058 0.94 SMN1; SMN2 (0.62) SMPD1HDAC1HDAC8HDAC6RAB9A
SCHEMBL30820546 0.94 SMN1; SMN2 (0.62) SMPD1HDAC1HDAC8HDAC6RAB9A
SCHEMBL2063068 0.94 SMN1; SMN2 (0.73) SMPD1HDAC1HDAC8HDAC6RAB9A
SCHEMBL2188210 0.94 SMPD1 (0.76) SMPD1HDAC1HDAC8HDAC6RAB9A
SCHEMBL17835716 0.92 SMPD1 (0.62) SMPD1HDAC1HDAC8HDAC6RAB9A
SCHEMBL18031233 0.92 SMN1; SMN2 (0.60) SMPD1HDAC1HDAC8HDAC6RAB9A
Bicarbonate SCHEMBL5499350 0.90 SMN1; SMN2 (0.68) SMPD1HDAC1HDAC8HDAC6RAB9A
Bicarbonate SCHEMBL5499351 0.90 SMN1; SMN2 (0.68) SMPD1HDAC1HDAC8HDAC6RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4678637-A1 NOVEL FLAVONE DERIVATIVE AND USE THEREOF IN ALLEVIATING PULMONARY FIBROSIS A-chembio Co., Ltd (KR) 2026-01-14 EP disclosed
US-20240336588-A1 COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS AVANTI BIOSCIENCES, INC. 2024-10-10 US disclosed
WO-2024186175-A1 NOVEL FLAVONE DERIVATIVE AND USE THEREOF IN ALLEVIATING PULMONARY FIBROSIS 주식회사 에이켐바이오 2024-09-12 WO disclosed
US-20240300913-A1 FLAVONE DERIVATIVE AND USE THEREOF FOR IMPROVING PULMONARY FIBROSIS A-CHEMBIO CO., LTD (KR) 2024-09-12 US disclosed
EP-4370113-A1 COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS Avanti Biosciences Inc. (US) 2024-05-22 EP disclosed
WO-2023288020-A1 COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS AVANTI BIOSCIENCES INC. (US) 2023-01-19 WO disclosed
WO-2023288020-A1 COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS AVANTI BIOSCIENCES INC. (US) 2023-01-19 WO disclosed
US-7745490-B2 Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies PROTEOTECH, INC. (US) 2010-06-29 US disclosed
US-7745490-B2 Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies PROTEOTECH, INC. (US) 2010-06-29 US disclosed
US-7745490-B2 Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies PROTEOTECH, INC. (US) 2010-06-29 US disclosed
US-20090060838-A1 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES PROTEOTECH INC. 2009-03-05 US disclosed
US-20090060838-A1 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES PROTEOTECH INC. 2009-03-05 US disclosed
US-20090060838-A1 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES PROTEOTECH INC. 2009-03-05 US disclosed
EP-1751097-A1 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES Proteotech, Inc. (US) 2007-02-14 EP disclosed
US-20060199838-A1 Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies PROTAMED, INC. 2006-09-07 US disclosed
WO-2005113489-A1 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES PROTEOTECH, INC. (US) 2005-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090060838-A1 SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES IAPP, SNCA, BACE2 SMPD1 410/4885HDAC1 3282/4885HDAC8 3097/4885
US-20240336588-A1 COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS MPO, GPX4, GPX1 SMPD1 2570/4885HDAC1 658/4885HDAC8 786/4885
US-20240300913-A1 FLAVONE DERIVATIVE AND USE THEREOF FOR IMPROVING PULMONARY FIBROSIS HGF, FN1, SMAD2 SMPD1 3606/4885HDAC1 2640/4885HDAC8 1650/4885
US-20060199838-A1 Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies IAPP, SNCA, BACE2 SMPD1 477/4885HDAC1 2950/4885HDAC8 2373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.